Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm Female|Breast Cancer|Breast Carcinoma|Breast Tumor
Interventions: DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Bicalutamide
Sponsor: Providence Health & Services
Collaborators: Bristol-Myers Squibb|Memorial Sloan Kettering Cancer Center